The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

NCT04329728 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoid Malignancies

Interventions

DRUG: AVM0703

Sponsor

AVM Biotechnology Inc

Collaborators

[object Object]